(PTCT) PTC Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US69366J2006

Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, Evrysdi

PTCT EPS (Earnings per Share)

EPS (Earnings per Share) of PTCT over the last years for every Quarter: "2020-03": -1.81, "2020-06": -2.78, "2020-09": -1.03, "2020-12": -1.08, "2021-03": -1.83, "2021-06": -1.68, "2021-09": -1.89, "2021-12": -2.03, "2022-03": -1.78, "2022-06": -2.13, "2022-09": -1.53, "2022-12": -2.35, "2023-03": -1.88, "2023-06": -2.66, "2023-09": -1.76, "2023-12": -2.06, "2024-03": -1.2, "2024-06": -1.29, "2024-09": -1.39, "2024-12": -0.85, "2025-03": 10.03,

PTCT Revenue

Revenue of PTCT over the last years for every Quarter: 2020-03: 68.259, 2020-06: 75.239, 2020-09: 118.404, 2020-12: 118.864, 2021-03: 117.942, 2021-06: 116.676, 2021-09: 138.743, 2021-12: 165.228, 2022-03: 148.735, 2022-06: 165.526, 2022-09: 217.127, 2022-12: 167.412, 2023-03: 220.382, 2023-06: 213.808, 2023-09: 196.576, 2023-12: 307.056, 2024-03: 210.118, 2024-06: 186.704, 2024-09: 196.786, 2024-12: 213.172, 2025-03: 1176.096,

Description: PTCT PTC Therapeutics

PTC Therapeutics Inc (NASDAQ:PTCT) is a biopharmaceutical company that specializes in developing and commercializing treatments for rare genetic disorders. The companys product portfolio includes several approved therapies, such as Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza for aromatic L-amino acid decarboxylase deficiency, and Evrysdi for spinal muscular atrophy. PTC Therapeutics has a robust pipeline of investigational products, including Sepiapterin for phenylketonuria and PTC518 for Huntingtons disease.

The companys commercial success is driven by its ability to develop and market niche treatments for rare diseases, often with limited competition. PTC Therapeutics has established partnerships with major pharmaceutical companies, including F. Hoffman-La Roche Ltd. and Novartis Pharmaceuticals Corporation, to further expand its product offerings and development pipeline. The companys gene therapy product, Upstaza (Kebilidi), is a significant addition to its portfolio, offering a new treatment option for patients with AADC deficiency.

Analyzing the , we observe that PTCTs stock price is currently at $52.13, above its 20-day and 50-day simple moving averages (SMA20: $47.68, SMA50: $46.94). The stock has also demonstrated a relatively high average true range (ATR: 2.37 = 4.56%), indicating moderate volatility. With the 52-week high and low at $57.17 and $30.39, respectively, the stock is currently trading near the upper end of its recent range.

From a fundamental perspective, PTC Therapeutics has a market capitalization of $4.1 billion and a relatively low forward price-to-earnings ratio (P/E Forward: 6.36). However, the companys return on equity (RoE) is negative (-71.70), indicating that it is not yet profitable on a net income basis. Despite this, the companys pipeline and commercial products have the potential to drive future growth.

Forecasting future performance based on the and , we can expect PTCTs stock price to be influenced by its ability to advance its pipeline products, particularly Sepiapterin and PTC518, through clinical trials and regulatory approvals. If successful, these products could drive revenue growth and improve the companys profitability. Additionally, the companys existing commercial products, such as Upstaza and Evrysdi, are expected to continue generating revenue. With a strong pipeline and a solid commercial foundation, PTCTs stock price may continue to rise, potentially testing the resistance level at $55.3. However, failure to advance its pipeline or meet revenue expectations could lead to a decline in the stock price, potentially towards the support level at $48.3.

Additional Sources for PTCT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

PTCT Stock Overview

Market Cap in USD 3,979m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2013-06-20

PTCT Stock Ratings

Growth Rating 2.82
Fundamental 39.4
Dividend Rating 0.0
Rel. Strength 74.2
Analysts 4 of 5
Fair Price Momentum 44.89 USD
Fair Price DCF 57.21 USD

PTCT Dividends

Currently no dividends paid

PTCT Growth Ratios

Growth Correlation 3m 58.8%
Growth Correlation 12m 81.7%
Growth Correlation 5y -31.6%
CAGR 5y -1.89%
CAGR/Max DD 5y -0.03
Sharpe Ratio 12m 0.22
Alpha 39.42
Beta 1.772
Volatility 50.37%
Current Volume 1060.2k
Average Volume 20d 996.9k
What is the price of PTCT shares?
As of July 03, 2025, the stock is trading at USD 49.15 with a total of 1,060,210 shares traded.
Over the past week, the price has changed by +0.53%, over one month by +0.66%, over three months by +1.61% and over the past year by +61.73%.
Is PTC Therapeutics a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, PTC Therapeutics (NASDAQ:PTCT) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.44 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PTCT is around 44.89 USD . This means that PTCT is currently overvalued and has a potential downside of -8.67%.
Is PTCT a buy, sell or hold?
PTC Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PTCT.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0
What are the forecasts for PTCT share price target?
According to our own proprietary Forecast Model, PTCT PTC Therapeutics will be worth about 53.9 in July 2026. The stock is currently trading at 49.15. This means that the stock has a potential upside of +9.6%.
Issuer Target Up/Down from current
Wallstreet Target Price 62.8 27.8%
Analysts Target Price 61.1 24.4%
ValueRay Target Price 53.9 9.6%